Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Summary: Background: Dislipidaemia and increased levels of apolipoprotein B (apoB) in individuals with obesity are risk factors for development of cardiovascular disease (CVD). The aim of this study was to investigate the effect of weight loss and weight maintenance with and without liraglutide treatment on plasma lipid profiles and apoB. Methods: Fifty‐eight individuals with obesity (body mass index 34.5 ± 3.0 kg/m 2 [mean ± SD]) were included in this study. After 8 weeks on a very low‐calorie diet (800 kcal/day), participants were randomized to weight maintenance with meal replacements with or without liraglutide (1.2 mg daily) for 1 year. Plasma samples from before and after weight loss and after 1 year of weight maintenance were subjected to nuclear magnetic resonance‐based lipidomics analysis. Results: After an 8‐week low‐calorie diet, study participants lost 12.0 ± 2.9 kg (mean ± SD) of their body weight, which was reflected in their lipid profiles (80 out of 124 lipids changed significantly), including reduced levels of apoB, total cholesterol, free cholesterol, remnant cholesterol, triglycerides, low‐density lipoprotein and very low‐density lipoprotein subclasses. After 1 year of maintained weight loss, the majority of the lipids had returned to pre‐weight loss levels even though weight loss was successfully maintained in both groups. Interestingly, apoB levels remained low in the liraglutide treated group (apoB change: 0.03 ± 0.02 mmol/L, p = 0.4) in contrast to an increase in the control group (apoB change: 0.06 ± 0.07 mmol/L, p = 0.02). Conclusion: An 8‐week low‐calorie diet, in individuals with obesity, reduced plasma levels of lipids and the atherogenic marker apoB. After 1 year of weight maintenance, only study participants treated with liraglutide maintained reduced levels of apoB, despite similar body weight maintenance. Treatment with liraglutide may therefore reduce apoB levels and thus reflect lower CVD risk. Including apoB measurements in clinical practice when monitoring patients with dislipidemia or CVD might prove to be useful.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 6×
“Furthermore, treatment with liraglutide decreases cardiovascular mortality in individuals with T2D (the recent published LEADER study (26)); however, the underlying mechanism remains unknown.”
BackgroundInfluentialA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
HDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870 · cited 1×
“HDL-C is a known predictor of CVD; however, the causal link between HDL and atherosclerosis is still uncertain (45).”
BackgroundZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Genome-wide association study identifies multiple loci influencing human serum metabolite levels
Kettunen, J., Tukiainen, T., Sarin, A.-P., Ortega-Alonso, A., Tikkanen, E., Lyytikäinen, L.-P., Kangas, A. J., Soininen, P., Würtz, P., Silander, K., et al. (2012) · Nature Genetics · doi:10.1038/ng.1073 · Cited by 553
Lamarche, B., Moorjani, S., Lupien, P. J., Cantin, B., Bernard, P.-M., Dagenais, G. R., & Despre´s, J.-P. (1996) · Circulation · doi:10.1161/01.cir.94.3.273 · Cited by 476
Hu, T., Mills, K. T., Yao, L., Demanelis, K., Eloustaz, M., Yancy, W. S., Kelly, T. N., He, J., & Bazzano, L. A. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws264 · Cited by 417 · cited 1×
“Plasma HDL particles are highly heterogeneous in their physiochemical properties, metabolism and biological activity, and the HDL response is variable and affected both by weight loss and by the type of dietary intervention (38,39).”
BackgroundWürtz, P., Wang, Q., Kangas, A. J., Richmond, R. C., Skarp, J., Tiainen, M., Tynkkynen, T., Soininen, P., Havulinna, A. S., Kaakinen, M., et al. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001765 · Cited by 280
Franssen, R., Monajemi, H., Stroes, E. S. G., & Kastelein, J. J. P. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.003 · Cited by 270
Research works printed but not linked: 29
- 10.1210/jc.2015-3213 · DOI
- Knight JA, 2011, Diseases and disorders associated with excess body weight, Ann Clin Lab Sci., 41, 107
- 10.3390/nu5041218 · DOI · Paper page
- 10.1016/0009-8981(73)90375-6 · doi:10.1016/0009-8981(73)90375-6
- 10.1093/qjmed/hcp065 · DOI
- 10.1016/S0140-6736(01)07098-2 · DOI · Paper page
- 10.1161/01.ATV.0000035521.22199.C7 · DOI · Paper page
- Elovson J, 1988, Plasma very low density lipoproteins contain a single molecule of apolipoprotein B, J Lipid Res., 29, 1461, 10.1016/S0022-2275(20)38425-X · DOI · Paper page
- 10.1046/j.1365-2796.2003.01276.x · DOI · Paper page
- 10.1007/s11745-002-1010-3 · DOI
- 10.1016/S0140-6736(10)60484-9 · DOI · Paper page
- 10.1016/j.ahj.2004.07.009 · DOI · Paper page
- 10.1007/BF00274216 · DOI · Paper page
- 10.1093/oxfordjournals.aje.a010233 · DOI · Paper page
- 10.1111/j.1463-1326.2011.01357.x · DOI · Paper page
- 10.1002/phar.1507 · DOI · Paper page
- 10.1586/14779072.2015.1054810 · DOI · Paper page
- 10.2337/dc09-S315 · DOI · Paper page
- 10.1161/ATVBAHA.115.305479 · DOI
- 10.1007/s00125-009-1611-5 · DOI · Paper page
- 10.1039/b910205a · DOI · Paper page
- 10.1111/j.1365-2796.2012.02562.x · DOI · Paper page
- 10.1161/CIRCGENETICS.114.000216 · DOI · Paper page
- 10.1016/j.numecd.2014.06.010 · DOI
- 10.1152/ajpgi.00303.2004 · DOI · Paper page
- 10.1194/jlr.P900015-JLR200 · DOI · Paper page
- 10.1186/1475-2840-13-49 · DOI · Paper page
- 10.2174/1570161113666150615111951 · DOI
- 10.4065/mcp.2009.0517 · DOI
Cited by
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function
Stadler, J. T., & Marsche, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238985 · Cited by 200
Sandsdal, R. M., Juhl, C. R., Jensen, S. B. K., Lundgren, J. R., Janus, C., Blond, M. B., Rosenkilde, M., Bogh, A. F., Gliemann, L., Jensen, J.-E. B., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01765-z · Cited by 195
Self-citationGLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Rizzo, M., Nikolic, D., Patti, A. M., Mannina, C., Montalto, G., McAdams, B. S., Rizvi, A. A., & Cosentino, F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.05.012 · Cited by 152
Anholm, C., Kumarathurai, P., Pedersen, L. R., Samkani, A., Walzem, R. L., Nielsen, O. W., Kristiansen, O. P., Fenger, M., Madsbad, S., Sajadieh, A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.07.007 · Cited by 75
Self-citationGutierrez, A. D., Gao, Z., Hamidi, V., Zhu, L., Saint Andre, K. B., Riggs, K., Ruscheinsky, M., Wang, H., Yu, Y., Miller, C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100813 · Cited by 44
Pérez-Belmonte, L. M., Sanz-Cánovas, J., García de Lucas, M. D., Ricci, M., Avilés-Bueno, B., Cobos-Palacios, L., Pérez-Velasco, M. A., López-Sampalo, A., Bernal-López, M. R., Jansen-Chaparro, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851035 · Cited by 35
“In addition, treatment with a GLP-1 receptor agonist such as liraglutide has been associated with a maintained reduction in apoB levels, potentially contributing to a lower cardiovascular risk (42).”
BackgroundPremji, R., Nylen, E. S., Naser, N., Gandhi, S., Burman, K. D., & Sen, S. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0004 · Cited by 18
“34 The study done by Nikolic et al. 35 examined the effect of Liraglutide at maximum dose of 1.2 mg/day as an add on therapy to metformin in obese patients with T2DM and assessed the lipid subfractions by gel electrophoresis.”
Influential
Metadata
- Authors
- Engelbrechtsen, L., Lundgren, J., Wewer Albrechtsen, N. J., Mahendran, Y., Iepsen, E. W., Finocchietto, P., Jonsson, A. E., Madsbad, S., Holst, J. J., Vestergaard, H., Hansen, T., & Torekov, S. S.
- Venue
- Obesity Science & Practice
- Publisher
- Wiley
- Published
- 2017-11-21
- Volume
- 3
- Issue
- 4
- Pages
- 425-433
- ISSN
- 2055-2238 (ISSN-L)
- OpenAlex
- W2751664507
- Cited by
- 31
- References
- 16
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- The Danish Research Council for Health and Disease (ref. no: 11-107683, 11-107683)
- The Lundbeck Foundation
- The P Carl Petersen Foundation
- Tripartite Immunometabolism Consortium [TrIC]- Novo Nordisk Foundation (NNF15CC0018486)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.